Prostate cancer genomes sequenced by Broad and Dana Faber

From Biolecture.org
Revision as of 12:56, 7 March 2011 by J (talk | contribs) (Created page with "<p><a href="http://www.bionews.org.uk/page_89234.asp">http://www.bionews.org.uk/page_89234.asp</a></p> <h1 class="page-header">Letter abstract</h1> <hr class="separator" /> <p id...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

http://www.bionews.org.uk/page_89234.asp

Letter abstract


Nature Genetics 39, 645 - 649 (2007)
Published online: 1 April 2007 | doi:10.1038/ng2022

 

Genome-wide association study of prostate cancer identifies a second risk locus at 8q24

Meredith Yeager1,2, Nick Orr3, Richard B Hayes2, Kevin B Jacobs4, Peter Kraft5, Sholom Wacholder2, Mark J Minichiello6, Paul Fearnhead7, Kai Yu2, Nilanjan Chatterjee2, Zhaoming Wang1,2, Robert Welch1,2, Brian J Staats1,2, Eugenia E Calle8, Heather Spencer Feigelson8, Michael J Thun8, Carmen Rodriguez8, Demetrius Albanes2, Jarmo Virtamo9, Stephanie Weinstein2, Fredrick R Schumacher5, Edward Giovannucci10, Walter C Willett10, Geraldine Cancel-Tassin11, Olivier Cussenot11, Antoine Valeri11, Gerald L Andriole12, Edward P Gelmann13, Margaret Tucker2, Daniela S Gerhard14, Joseph F Fraumeni, Jr2, Robert Hoover2, David J Hunter2,5, Stephen J Chanock2,3 & Gilles Thomas2

Top

Recently, common variants on human chromosome 8q24 were found to be associated with prostate cancer risk. While conducting a genome-wide association study in the Cancer Genetic Markers of Susceptibility project with 550,000 SNPs in a nested case-control study (1,172 cases and 1,157 controls of European origin), we identified a new association at 8q24 with an independent effect on prostate cancer susceptibility. The most significant signal is 70 kb centromeric to the previously reported SNP, rs1447295, but shows little evidence of linkage disequilibrium with it. A combined analysis with four additional studies (total: 4,296 cases and 4,299 controls) confirms association with prostate cancer for rs6983267 in the centromeric locus (P = 9.42 times 10-13; heterozygote odds ratio (OR): 1.26, 95% confidence interval (c.i.): 1.13–1.41; homozygote OR: 1.58, 95% c.i.: 1.40–1.78). Each SNP remained significant in a joint analysis after adjusting for the other (rs1447295 P = 1.41 times 10-11; rs6983267 P = 6.62 times 10-10). These observations, combined with compelling evidence for a recombination hotspot between the two markers, indicate the presence of at least two independent loci within 8q24 that contribute to prostate cancer in men of European ancestry. We estimate that the population attributable risk of the new locus, marked by rs6983267, is higher than the locus marked by rs1447295 (21% versus 9%).